Hemosepermia after transrectal ultrasound-guided prostatic biopsy: a prospective study

ABSTRACT

Trans-rectal ultrasound [TRUS] is a safe, cost-effective, radiation-free imaging modality for evaluation of prostate. But unfortunately, hemospermia is known to be associated with TRUS-guided prostate biopsy. The aim of this study is to measure the incidence and risk factors of hemospermia in patients undergoing TRUS. A prospective observational study involving patients undergoing TRUS for suspected prostate cancer has been conducted at AI-Hussein and Sayed Galal Hospitals. Forty patients were included in the study. Most men [90% = 36 patient] undergoing TRUS-guided prostatic biopsy, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 4 [+/- 1.4] weeks. The number of ejaculations before the complete resolution of hemospermia was 6 [+/- 5.6]. None of the clinical and pathological factors was a significant predictor of the duration of hemospermia. Patients should be adequately counseled before TRUS-guided prostatic biopsy to avoid anxiety and alterations in sexual activity